SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of a group of businessmen white-collar workers dismissed
Layoffs
AbbVie’s Allergan Cuts Over 200 Staff After Botched Marketing Campaign
The layoffs will take effect on July 22 and particularly target those working in sales, data engineering and product management.
May 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
Former Chinook Board Member Indicted for Insider Trading Related to $3.2B Novartis Buy
Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to the DOJ’s allegations, used confidential information to conduct insider trading.
May 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN
HHS Secretary RFK Jr. removes the COVID-19 vaccine recommendation for healthy kids and pregnant women—the latest in a string of changes to vaccine policies; judge issues an order to halt HHS’ reorganization and mass layoff plans; Rocket Pharmaceuticals’ pivotal Danon disease trial is on hold after a patient death; and President Trump has named Mehmet Oz to spearhead his Most Favored Nation drug pricing policy.
May 28, 2025
 · 
2 min read
 · 
Heather McKenzie
Depressed woman with flying hair stand in the choppy water. Lost girl feels frustrated and confused thinking. Concept of psychological problem, mental disease and brain illness. Vector illustration.
Depression
Biogen’s Zurzuvae Strategy Shifts as OB/GYNs Rise to the Front Lines
Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in postpartum depression.
May 28, 2025
 · 
5 min read
 · 
Annalee Armstrong
Perspective way to invest money. Hands with dollar sign coins around yellow light bulb over blue background
Clinical research
Undeterred by Political, Economic Headwinds, Pharma Ups R&D Investment in 2024 and Beyond
R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.
May 28, 2025
 · 
12 min read
 · 
Tristan Manalac
Joint pain anatomy medical concept
Pain
Lilly Follows Vertex Into Non-Opioid Pain With up to $1B SiteOne Buy
The acquisition of SiteOne provides a bit of diversification for Lilly, which has burrowed into the obesity and diabetes space with mega-blockbuster tirzepatide and several follow-on molecules.
May 27, 2025
 · 
2 min read
 · 
Annalee Armstrong
ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities
Neuroscience
Epilepsy Biotech Nabs up to $570M in Deal With Italy’s Angelini Plus $140M Fundraising
In addition to a $140 million series D, GRIN Therapeutics has signed a global licensing deal for the epilepsy disorder drug radiprodil worth $50 million upfront.
May 27, 2025
 · 
1 min read
 · 
Annalee Armstrong
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Funding
Novo-Backed GlycoEra Raises $130M To Advance Protein Degraders for Precision Immunology
GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific kinase myasthenia gravis and pemphigus.
May 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Red round circle with a pause button or icon against yellow background.
Gene therapy
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
Acute systemic infection caused the patient to develop fatal capillary leak syndrome, highlighting the unpredictability of gene therapies and potentially challenging investment in the space, analysts say.
May 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS